188 related articles for article (PubMed ID: 29938870)
21. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.
Sakamoto S; Yamada T; Terazaki Y; Yoshiyama K; Sugawara S; Takamori S; Matsueda S; Shichijo S; Yamada A; Noguchi M; Itoh K; Hattori N; Kohno N; Sasada T
Clin Lung Cancer; 2017 Nov; 18(6):e385-e394. PubMed ID: 28416261
[TBL] [Abstract][Full Text] [Related]
22. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
23. Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer.
Sasada T; Noguchi M; Yamada A; Itoh K
Hum Vaccin Immunother; 2012 Sep; 8(9):1309-13. PubMed ID: 22894962
[TBL] [Abstract][Full Text] [Related]
24. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ
Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
[TBL] [Abstract][Full Text] [Related]
26. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
27. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
[TBL] [Abstract][Full Text] [Related]
28. Personalized peptide vaccine for treatment of advanced cancer.
Sasada T; Yamada A; Noguchi M; Itoh K
Curr Med Chem; 2014; 21(21):2332-45. PubMed ID: 24524766
[TBL] [Abstract][Full Text] [Related]
29. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
30. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
Noguchi M; Sasada T; Itoh K
Cancer Immunol Immunother; 2013 May; 62(5):919-29. PubMed ID: 23197273
[TBL] [Abstract][Full Text] [Related]
31. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
Kawano K; Tsuda N; Waki K; Matsueda S; Hata Y; Ushijima K; Itoh K; Yamada A; Kamura T
Cancer Sci; 2015 Sep; 106(9):1111-7. PubMed ID: 26122553
[TBL] [Abstract][Full Text] [Related]
32. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
33. Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.
Araki H; Pang X; Komatsu N; Soejima M; Miyata N; Takaki M; Muta S; Sasada T; Noguchi M; Koda Y; Itoh K; Kuhara S; Tashiro K
Cancer Immunol Immunother; 2015 Dec; 64(12):1565-73. PubMed ID: 26428930
[TBL] [Abstract][Full Text] [Related]
34. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
Suekane S; Yutani S; Yamada A; Sasada T; Matsueda S; Takamori S; Toh U; Kawano K; Yoshiyama K; Sakamoto S; Sugawara S; Komatsu N; Yamada T; Naito M; Terasaki M; Mine T; Itoh K; Shichijo S; Noguchi M
Int J Oncol; 2020 Jun; 56(6):1479-1489. PubMed ID: 32236612
[TBL] [Abstract][Full Text] [Related]
35. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.
Noguchi M; Mine T; Komatsu N; Suekane S; Moriya F; Matsuoka K; Yutani S; Shichijo S; Yamada A; Toh U; Kawano K; Azuma K; Uemura H; Okuno K; Matsumoto K; Yanagimoto H; Yamanaka R; Oka M; Todo S; Sasada T; Itoh K
Cancer Biol Ther; 2010 Dec; 10(12):1266-79. PubMed ID: 20935522
[TBL] [Abstract][Full Text] [Related]
36. [Personalized peptide vaccination].
Itoh K; Takahashi R; Yoshitomi M; Terasaki M; Noguchi M
Nihon Rinsho; 2012 Dec; 70(12):2118-23. PubMed ID: 23259383
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.
Noguchi M; Mine T; Yamada A; Obata Y; Yoshida K; Mizoguchi J; Harada M; Suekane S; Itoh K; Matsuoka K
Oncol Res; 2007; 16(7):341-9. PubMed ID: 17518272
[TBL] [Abstract][Full Text] [Related]
38. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.
Miyagi Y; Imai N; Sasatomi T; Yamada A; Mine T; Katagiri K; Nakagawa M; Muto A; Okouchi S; Isomoto H; Shirouzu K; Yamana H; Itoh K
Clin Cancer Res; 2001 Dec; 7(12):3950-62. PubMed ID: 11751487
[TBL] [Abstract][Full Text] [Related]
39. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
[TBL] [Abstract][Full Text] [Related]
40. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
Parmiani G; Castelli C; Dalerba P; Mortarini R; Rivoltini L; Marincola FM; Anichini A
J Natl Cancer Inst; 2002 Jun; 94(11):805-18. PubMed ID: 12048268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]